ALR Technologies Announces Patent Grant for Predictive A1C and Successful Results from Singapore General Hospital-led Study

SINGAPORE,Sept. 28,2023 --ALR TechnologiesSGLtd.("ALRT"orthe"Company")(OTCQB: ALRTF),a diabetes management company,announces the patent application titled Method and System of Monitoring a Diabetes Treatment Plan ("Predictive A1c") has been granted in Singapore and has receivednoticeofallowanceintheUnitedStates.

Predictive A1c is the Company's cornerstone,the first of its kind U.S Food & Drug Administration ("FDA") cleared Diabetes Management Solution that shifts patient self-management to active patient management while providing best practice guidelines and ensuring adherence to care plans. Predictive A1c is owned by Sidney Chan,Chairman and CEOof ALRT. The Company hasthe right to utilize PredictiveA1cpursuanttoaninformallicensewithMr.Chanandexpectstoacquiretheintellectual property in the next 12 months. Final steps have been taken in the United States Patent and Trademark Officeforissuance oftheUSpatentforPredictiveA1c,andtheUSpatentisexpectedtograntinthe coming weeks. The Company expects Predictive A1c patent applications submitted in other jurisdictionstoadvance tograntin2024.

Additionally,ALRT announces the successful completion of its 24-week study led by Singapore General Hospital("SGH").Atotalof25insulin-treatedpatientswithtype2diabetesmellituswereenrolledinto the ALRT Diabetes Solution platform. The patients performed twice daily capillary blood glucose checks andweeklyglucometeruploads.Theplatformthenprovidedinsulindosesuggestionsandalertstothe physicians. All patients experienced a mean drop of 1.2 percent in glycated hemoglobin (HbA1c). The findings from the study validated the significant value that ALRT Diabetes Solution may potentially bringtopatients andhealthcareproviders.TheresultswerepresentedattherecentInternationalDiabetes Federation Western Pacific Congress 2023 in Kyoto,Japan,and are expected to be published in the future.

"We are pleased to see the continued success of the ALRT Diabetes Solution from the outcome of this SGH study that replicated the results of our previous clinical trials in Canada and Kansas City,all of which have resulted in a 1.2 percent drop in mean A1c," commented Sidney Chan,Chairman and CEO of ALRT. "The successful conclusion of this study gives ALRT the clinical evidence needed to continue forwarding our efforts in deploying ALRT Diabetes Solution in ASEAN territories. On top of that,receiving the patent grant for Predictive A1c protects our clinically proven effective diabetes management system against would be competitors while securing our competitive advantage over other software platforms."

AboutALRTechnologiesSGLtd.

ALRT is a data management company that developed the ALRT Diabetes Solution,a comprehensive approach to diabetes care that includes an FDA-cleared and HIPAA compliant diabetes management system that collects data directly from blood glucose meters and continuous glucose monitoring devices,and Predictive A1C algorithm to track treatment success between lab reports and an FDA- cleared Insulin Dosing Adjustment program. The overall goal is to optimize diabetes drug therapies to drive improved patient outcomes.

In addition,the animal health division of ALRT has developed the GluCurve Pet CGM; a solution to assist veterinarians better determine the efficacy of insulin treatments and to help to identify the appropriate

dose and frequency of administration for companion animals,thereby delivering the same optimization ofdiabetic drugtherapiestopetsastohumans.

More information about ALRT and the GluCurve Pet CGM can be found at www.alrt.com and https://www.glucurve.com/Index.

InvestorContact

InvestorRelations:ir@alrt.com

Animal Health Inquiries: animalhealth@alrt.comMedia:Media@alrt.com

US: +1 804 554 3500

Singapore: +65 3129 2924

ALRTechnologiesSG Ltd.Forward-LookingStatement

Thispressreleasecontains "forward-lookingstatements"within themeaningofthesafeharborprovisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "goal," "seek," "believe," "project," "estimate," "expect," "strategy," "future," "likely," "may," "should," "will" and similar references to future periods. Examples of forward-looking statements include,among others,statements we make regarding future sales and revenues,expected levels of product inventory and demand,strategy for customer retention,growth,product distribution,market penetration and expansion,financial results and reserves,and strategy for risk management. Forward-looking statements are neither historical facts nor assurances of future performance. Instead,they are based only on our current beliefs,expectations and assumptions regarding the future of our business,future plans and strategies,projections,anticipated events and trends,the economy and other future conditions. Because forward-looking statements relate to the future,they are subject to inherent uncertainties,risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially from those indicated in the forward-looking statements. Therefore,you should not relyon any of these forward-looking statements. Moreinformationontheserisks andotherpotentialfactors thatcouldaffect ourbusiness,reputation,resultsofoperations,financialcondition,andstockprice is includedinourfilingswiththeSECandsubsequentfilings.Anyforward-lookingstatementmadebyusin this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement,whether written or oral,that may be made from time to time,whether as a result of new information,future developments or otherwise.